Sangamo Therapeutics Expects FY24 GAAP Basis Total Operating Expenses Of Approximately $150M - $170M
Sangamo Therapeutics Expects FY24 GAAP Basis Total Operating Expenses Of Approximately $150M - $170M
Sangamo therapeutics預計 FY24 GAAP基礎的總營業費用約爲1.5億美元至1.7億美元。
It expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $13 million, impairment expense of approximately $6 million, and depreciation and amortization of approximately $7 million, in the range of approximately $125 million to $145 million in 2024.
預計在2024年，非GAAP總營業費用將在大約12500萬至14500萬區間內，不包括約1300萬美元的估算非現金股票補償費用、約600萬美元的減值費用和約700萬美元的折舊和攤銷費用。